Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ACS Clinical Congress 2024
SOHO 2024
Timely Topics
2024 ASTRO Annual Meeting
NCCN Oncology Policy Summit
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
About Us
Advertisement
Advertisement
Advertisement
Oct
22
Today In Oncology
Accelerated Approval for Bladder Cancer Drug to Be Withdrawn After Negative Trial
Cancer Diagnoses May Be Linked to Lasting Financial Challenges
Rogaratinib/Atezolizumab in Cisplatin-Ineligible FGFR mRNA-Overexpressing Urothelial Cancer
ACS Program May Reduce Postsurgical Mortality, Improve Care Among Older Patients
Regorafenib in Refractory Advanced Gastric Cancer
View More
Advertisement